Document is current
Any future updates will be listed below
-
Authors
Schubert, Maren
Bertoglio, Federico
Steinke, Stephan
Heine, Philip Alexander
Ynga-Durand, Mario Alberto
Maass, Henrike
Sammartino, Josè Camilla
Cassaniti, Irene
Zuo, Fanglei
Du, Likun
Korn, Janin
Milošević, Marko
Wenzel, Esther Veronika
Krstanović, Fran
Polten, Saskia
Pribanić-Matešić, Marina
Brizić, Ilija
Baldanti, Fausto
Hammarström, Lennart
Dübel, Stefan
Šustić, Alan
Marcotte, Harold
Strengert, Monika
Protić, Alen
Piralla, Antonio
Pan-Hammarström, Qiang
Čičin-Šain, Luka
Hust, Michael http://orcid.org/0000-0003-3418-6045
-
Funding
Funding for this research was provided by:
H2020 European Research Council (101003650)
MWK Niedersachsen (14-76103-184 CORONA-2/2)
Deutsche Herzstifung (Menschliche monoklonale Antikörper gegen SARS-CoV2 zur Prophylaxe gegen COVID-19 bei vorerkrankten Risikopatienten – Unterstützung der Entwicklung)
Swedish Research Council (-)
DFG (FOR3004)
Helmholtz-Gemeinschaft (EU-Partering PIE-0008 and Helmholtz campaign COVIPA)
Technische Universität Braunschweig
- License Information
-
More Information
Article History
Received: 30 December 2021
Accepted: 21 February 2022
First Online: 3 March 2022
Declarations
:
: This study was conducted following the Declaration of Helsinki Ethical Principles. Approval was given from the ethical committee of the Technische Universität Braunschweig (Ethik-Kommission der Fakultät 2 der TU Braunschweig, approval number FV-2020-02). The study in Croatia was approved by the Ethics committee of the Rijeka Clinical Hospital Center (2170-29-02/1-20-2). The study in Italy was performed under the approval of the Institutional Review Board of Policlinico San Matteo (protocol number P_20200029440). The study in Sweden was approved by the ethics committee in Stockholm (Dnr 2020-02646). All the participants provided informed consent.
: Not applicable.
: MS1, FB1, SS, PAH, SD, and MH are inventors on a patent application on blocking antibodies against SARS-CoV-2. SD and MH are co-founders and shareholders of CORAT Therapeutics GmbH, a company founded for clinical and regulatory development of COR-101, an antibody for the treatment of hospitalized COVID-19 patients. SD and EVW are co-founders and shareholders of Abcalis GmbH, a company producing antibodies for diagnostics of SARS-CoV-2.
